Value based drug pricing could increase NHS drugs billBMJ 2011; 342 doi: http://dx.doi.org/10.1136/bmj.d1759 (Published 17 March 2011) Cite this as: BMJ 2011;342:d1759
- Nigel Hawkes
Government proposals to change the way drugs are priced in the United Kingdom could increase the bill to the NHS without a corresponding benefit to patients, the NHS Confederation warns.
In its response to the Department of Health for England’s consultation on value based pricing of drugs, the confederation, which represents more than 95% of the organisations in the NHS, warns of a loss of transparency, the danger of politicising the process, and the likelihood that the scheme will provide little real incentive to drug companies to innovate.
Even drugs whose price reflects their value to the NHS may be poor value for money when compared with other treatment options such as earlier detection, surgery, or radiotherapy, the confederation says. Decisions are to be based on “expert advice,” which suggests that decisions may not be fully …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial